Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vadadustat - Akebia Therapeutics

Drug Profile

Vadadustat - Akebia Therapeutics

Alternative Names: AKB-6548; MT 6548; PG-1016548

Latest Information Update: 20 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Procter & Gamble
  • Developer Akebia Therapeutics; Mitsubishi Tanabe Pharma Corporation
  • Class Antianaemics; Chlorophenols; Pyridines; Small molecules
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Anaemia

Most Recent Events

  • 10 Nov 2019 Updated efficacy and adverse events data from the phase III J01 trial in Anaemia released by Akebia Therapeutics
  • 10 Nov 2019 Updated efficacy and adverse events data from the phase III J03 trial in Anaemia released by Akebia Therapeutics
  • 09 Nov 2019 Akebia Therapeutics plans to launch vadadustat worldwide next year
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top